Retatrutide and the Rise of Weight Loss Injections: What It Means for Your Skin
Retatrutide side effects and rapid weight loss can affect skin, face and muscle. Here’s how to support your skin alongside GLP-1 therapy.

Home > Is Retatrutide Available in Australia? Current Status and What to Consider
Retatrutide side effects and rapid weight loss can affect skin, face and muscle. Here’s how to support your skin alongside GLP-1 therapy.
Is retatrutide available in Australia? Not yet. See the TGA status, Phase 3 trial results, safety warnings and what your real options are today.
Notox vs anti-wrinkle injections explained: one relaxes muscle, the other lifts skin. Compare onset, longevity and downtime.
Wondering how does SQT Bio-Microneedling works alongside other treatments? Our guide breaks down what you can stack for your skin concern.
Learn what to expect after SQT Bio-Microneedling and the proper aftercare routine, including how to use your recovery serum and what to avoid.
Is retatrutide available in Australia? No. As of October 2026, the Therapeutic Goods Administration (TGA) hasn’t approved it, it isn’t approved for prescription use, and Lilly, the company that developed retatrutide, shares that it’s legally available only to participants in its clinical trials.
Here’s where things stand, what the science shows, and what your real options are right now.
Retatrutide is an investigational once-weekly injection from Eli Lilly. It activates three hormone receptors at once (GIP, GLP-1 and glucagon), which is why it’s called a triple agonist.
Semaglutide (Ozempic and Wegovy) targets GLP-1 alone. Tirzepatide (Mounjaro) mimics two hormones. Retatrutide adds a third.
TRIUMPH-1 followed 2,339 adults with obesity or overweight (without diabetes) for 80 weeks. Those on the 12 mg dose lost an average of 28.3% of their body weight, compared with 2.2% on placebo. The 4 mg dose averaged 19.0% according to reports in May 2026. TRIUMPH-3, in people with severe obesity and cardiovascular disease, reported losses of up to 22.6% in July 2026.
For context, tirzepatide’s top dose averaged 20.9% over 72 weeks in SURMOUNT-1. In a head-to-head trial, tirzepatide averaged 20.2% against 13.7% for semaglutide. The trials differ in populations and timeframes, so treat these comparisons as a guide only.
Two caveats matter. These are topline figures reported by Lilly, with a peer-reviewed publication still to come. Side effects are also real. At 12 mg, nausea affected 42.4% of participants (14.8% on placebo), dysaesthesia (unusual skin sensations) affected 12.5% (0.9% on placebo), and 11.3% stopped treatment because of side effects (4.9% on placebo).
Not yet. The TGA confirms retatrutide hasn’t been approved by it or any comparable regulator. Lilly said in July that it will submit to the FDA in the first quarter of 2027, and regulators will then need time to review. We haven’t seen an announced TGA submission date.
Allowing for review time, late 2028 to early 2029 is a realistic window for Australian approval. That’s our estimate, not an official date, and it could shift. PBS subsidy is a separate decision again.
In April 2026, the TGA warned about rising imports of unapproved peptides and named retatrutide among them. Reports included severe allergic reactions that led to hospitalisation. Victorian health authorities have recorded six cases of acute liver injury in people who used an unapproved product labelled retatrutide. In September, TGA testing of one such product found undeclared semaglutide and no retatrutide.
“Research use only” means a product was made for laboratory work, not for people. Nobody checks the dose, purity or sterility before it’s injected. The TGA’s Chief Medical Adviser says the biggest risks are not knowing what’s in the vial, how much it contains, or whether it’s sterile.
Body Catalyst doesn’t prescribe or supply retatrutide, and we’d encourage you to steer clear of any product sold under its name. If you’ve already used one and feel unwell, see your GP promptly.

So is retatrutide available in Australia through a legitimate channel? It isn’t, but you have more options than the headlines suggest:
Weight loss on these medicines is mostly fat. In SURMOUNT-1, tirzepatide-induced weight loss was roughly three-quarters fat and one-quarter lean tissue, with lean tissue including water, organs, and muscle. Even so, plenty of people tell us their body feels softer and their skin looser after a big drop. We cover this in our guide to GLP-1 side effects.
Body Catalyst treatments are available today and target those concerns:
These treatments sit alongside weight-loss medicine and shape, tone and tighten what’s left. Results vary from person to person.
Already on a GLP-1, or thinking about it? Book a complimentary consultation, and a Body Catalyst therapist will map out which treatments suit your goals and timing.
Book a complimentary consultation with our Aesthetic & Wellness Therapists. During your complimentary consultation, your body expert will help answer any questions you may have about the technology and treatment process. From there, we will work with you to customise and recommend the best treatment program options to help you achieve your body goals.
Not sure which treatment is best for you? Call us today and speak with our Aesthetic & Wellness Therapists to discuss your body goals.